Research
Lentinan (Shiitake Beta-Glucan)
26 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis.
Meta-analysis of 52 RCTs evaluating the efficacy and safety of lentinan for injection combined with cisplatin in treating malignant pleural effusion. The combination improved treatment effects and quality of life, and decreased gastrointestinal reactions compared to cisplatin alone.
Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer.
Meta-analysis of 31 RCTs with 2729 patients evaluating injectable Lentinan combined with chemotherapy for gastric cancer. Lentinan adjunctive therapy improved treatment efficacy, immune cell markers, and quality of life compared to chemotherapy alone, with no serious adverse effects.
Lentinan combined with cisplatin for the treatment of non-small cell lung cancer.
Systematic review of 17 RCTs involving 1390 patients with non-small cell lung cancer, evaluating lentinan combined with cisplatin thoracic injection. Meta-analysis showed significant clinical efficacy and improved quality of life, with lower incidence of adverse reactions compared to cisplatin alone. However, methodological quality was low, and further rigorous studies are needed.
Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials.
Systematic review and meta-analysis of 65 RCTs involving 4,080 patients to evaluate the efficacy of Lentinan plus chemical irritants for malignant pleural effusion. Lentinan with cisplatin significantly improved complete response and quality of life, and decreased the risk of treatment failure and side effects.
Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China.
Systematic review of 135 clinical studies in China evaluating lentinan, a polysaccharide from Lentinula edodes, in cancer treatment. The review covers 9474 cases across various cancer types, showing lentinan's positive effects on quality of life and enhancing chemotherapy and radiation therapy efficacy.
Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis.
Meta-analysis of 17 clinical studies with 1423 patients evaluating adjuvant lentinan combined with chemotherapy for advanced cancer. Lentinan improved 1-year survival rate, overall response rate, and reduced progressive disease and adverse events. The effect was consistent across gastrointestinal and lung cancer subgroups, but sustained efficacy on survival remains unclear.
A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer.
Meta-analysis of 12 clinical studies with 950 participants evaluating lentinan injection combined with chemotherapy for NSCLC. The combined treatment improved the objective response rate and decreased chemotherapy-related toxicity compared to chemotherapy alone.
Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.
Individual patient data meta-analysis of 5 trials with 650 patients evaluated the effect of lentinan in combination with chemotherapy for advanced gastric cancer. Lentinan significantly prolonged overall survival compared to chemotherapy alone, with a hazard ratio of 0.80.
A Quality-of-Life Study in Healthy Adults Supplemented with Lentinex® Beta-Glucan of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes).
RCT of 63 healthy adults evaluating the effect of Lentinex beta-glucan supplementation on well-being. Participants taking Lentinex showed a statistically significant improvement in well-being compared to placebo, especially those with lower initial well-being.
Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
Randomized phase III study comparing S-1 alone versus S-1 plus lentinan in 309 patients with unresectable or recurrent gastric cancer. The study found no improvement in overall survival and a significantly worse time-to-treatment failure in the S-1 plus lentinan group compared to S-1 alone.
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
RCT of 50 esophageal carcinoma patients comparing chemotherapy alone to chemotherapy combined with lentinan. The experimental group showed significantly greater improvement in general condition, symptoms, signs, and quality of life. Immune function was enhanced with increased IL-2, IL-6, and IL-12 levels and decreased IL-4, IL-5, and IL-10 levels.
Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.
RCT assessing the efficacy of a combination therapy of lentinan, RFA, and TACE in 78 HCC patients. The combination group showed significantly higher tumour necrosis, lower recurrence rate, and increased mean survival duration compared to other groups.
Supplementation with a soluble β-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly.
A double-blind, crossover, placebo-controlled trial evaluated the effect of Lentinex, a beta-glucan from Lentinus edodes mycelium, on the immune response in 42 healthy elderly subjects. Lentinex was found to be safe and increased the number of circulating B-cells, although other immune factors were not significantly altered.
Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer.
Multicenter clinical study of superfine dispersed lentinan in 27 patients with unresectable or recurrent gastric cancer. The study found no adverse events related to lentinan, with a median survival time of 17.1 months. Quality of life scores at 12 weeks correlated with survival times, suggesting lentinan may improve longevity.
Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
Multi-center study on the effectiveness of superfine dispersed lentinan in 29 patients with advanced pancreatic cancer. The study found that lentinan is safe and effective, improving survival times and quality of life scores. Median survival time was 12.1 months, with 20% of patients alive for 3 years.
Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life.
Prospective randomized study evaluating the effects of lentinan (LNT) in combination with S-1 and paclitaxel on quality of life (QOL) in gastric cancer patients. The study found that the total QOL score was significantly elevated in the LNT 12-week group compared to the LNT 6-week group.
Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers.
RCT evaluating lentinan's effect on Th1/Th2 balance in 28 patients with digestive cancers. Lentinan treatment increased CD4+ IFN-gamma+ T-cell percentages and decreased CD4+ IL-4+ and CD4+ IL-6+ T-cell percentages, suggesting improved Th1/Th2 balance.
A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
A multi-institutional randomized prospective study investigated the effects of lentinan in combination with tegafur and cisplatin on survival and quality of life in advanced gastric cancer patients. The lentinan group showed significantly longer median survival and improved quality of life, particularly in appetite and sleep quality, compared to the control group.
A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.
Two phase I/II placebo-controlled trials were conducted on 98 HIV-positive patients to assess the immune modulating properties of lentinan, a beta 1-->3 glucan from Shiitake mushroom. The study found lentinan to be well-tolerated with mild side effects and showed a trend toward increased CD4 cells and neutrophil activity, though not statistically significant. A subsequent trial indicated a mean increase in CD4 cells when lentinan was combined with didanosine.
Clinical evaluation of anti-tumor effects of Lentinan combined with chemotherapy in the treatment of various malignancies.
The paper evaluates the anti-tumor effects of Lentinan when combined with chemotherapy in the treatment of various malignancies. No abstract is available to provide further details.
Lentinan potentiates immunity and prolongs the survival time of some patients.
The study analyzed the immunological response of patients to lentinan treatment. Patients with a specific increase in CD8+ lymphocyte ratios and decreased levels of IL-6, G-CSF, and PGE2 after lentinan administration showed prolonged survival, suggesting enhanced immune potential.
A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.
Phase II controlled study assessing the safety and efficacy of lentinan combined with didanosine (ddI) in HIV patients with CD4 levels of 200-500 cells/mm3. The combination significantly increased CD4 levels up to 38 weeks, suggesting lentinan's potential in future multi-drug HIV studies.
Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey.
RCT and 4-year follow-up survey of lentinan (LNT) in combination with chemotherapeutic agent tegafur (FT) in patients with advanced or recurrent stomach cancer. LNT showed remarkable lifespan prolongation effects and improved survival rates at 1, 2, and 3 years. Side effects were transitional and not serious.
Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis
The study describes the development of lentinan-based nanoparticles loaded with budesonide for targeted treatment of ulcerative colitis. Lentinan serves as a natural carrier, enhancing budesonide's stability and macrophage-targeting ability, leading to significant anti-inflammatory effects in mice.
The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass.
RCT of 25 adults undergoing coronary artery bypass grafting to assess the effect of preoperative lentinan administration. Lentinan group showed maintained natural killer cell activity and rapid recovery of CD4-positive cells compared to control.
Recent progress in immunopharmacology and therapeutic effects of polysaccharides.
The paper discusses the antitumour activity and therapeutic effects of lentinan, a polysaccharide, in cancer patients. Lentinan has shown to prolong life-span in patients with advanced and recurrent cancers and increase resistance to infections, including AIDS, with minimal side effects.